207 related articles for article (PubMed ID: 15681535)
1. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; Semiond D; deJonge MJ; Eskens FA; ter Steeg J; Selleslach J; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
J Clin Oncol; 2005 Feb; 23(4):889-98. PubMed ID: 15681535
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
[TBL] [Abstract][Full Text] [Related]
3. A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Jefford M; Michael M; Rosenthal MA; Davis ID; Green M; McClure B; Smith J; Waite B; Zalcberg J
Invest New Drugs; 2004 Apr; 22(2):185-92. PubMed ID: 14739668
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
8. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.
Cassidy J; Dirix L; Bissett D; Reigner B; Griffin T; Allman D; Osterwalder B; Van Oosterom AT
Clin Cancer Res; 1998 Nov; 4(11):2755-61. PubMed ID: 9829739
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
[TBL] [Abstract][Full Text] [Related]
10. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
[TBL] [Abstract][Full Text] [Related]
11. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
Michaelson MD; Ryan DP; Fuchs CS; Supko JG; Garcia-Carbonero R; Paul Eder J; Clark JW
Cancer; 2003 Jan; 97(1):148-54. PubMed ID: 12491516
[TBL] [Abstract][Full Text] [Related]
12. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
Saeki T; Takashima S; Terashima M; Satoh A; Toi M; Osaki A; Toge T; Ohno S; Nomura N; Fukuyama Y; Koizumi W; Taguchi T
Int J Clin Oncol; 2005 Feb; 10(1):51-7. PubMed ID: 15729602
[TBL] [Abstract][Full Text] [Related]
13. A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine.
Hirawat S; Kolitz J; Lichtman SM; Allen SL; Villani G; Gonzales A; Fricano M; Budman DR
Cancer Invest; 2007; 25(3):148-53. PubMed ID: 17530484
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Goff LW; Benson AB; LoRusso PM; Tan AR; Berlin JD; Denis LJ; Benner RJ; Yin D; Rothenberg ML
Invest New Drugs; 2012 Feb; 30(1):290-8. PubMed ID: 20857171
[TBL] [Abstract][Full Text] [Related]
15. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Kuppens IE; Dansin E; Boot H; Feger C; Assadourian S; Bonneterre ME; Beijnen JH; Schellens JH; Bonneterre J
Clin Cancer Res; 2006 Jun; 12(12):3774-81. PubMed ID: 16778105
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Oh SC; Sur HY; Sung HJ; Choi IK; Park SS; Seo JH; Jeen YT; Chun HJ; Shin SW; Mok YJ; Kim JS; Kim YH
Br J Cancer; 2007 May; 96(10):1514-9. PubMed ID: 17473829
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
Goel S; Jhawer M; Rajdev L; Hopkins U; Fehn K; Baker C; Chun HG; Makower D; Landau L; Hoffman A; Wadler S; Mani S
Am J Clin Oncol; 2002 Oct; 25(5):528-34. PubMed ID: 12393999
[TBL] [Abstract][Full Text] [Related]
19. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Camidge DR; Gail Eckhardt S; Gore L; O'Bryant CL; Leong S; Basche M; Holden SN; Musib L; Baldwin J; Darstein C; Thornton D; Finn RS; Britten CD
Anticancer Drugs; 2008 Jan; 19(1):77-84. PubMed ID: 18043132
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Ramanathan RK; Ramalingam S; Egorin MJ; Belani CP; Potter DM; Fakih M; Jung LL; Strychor S; Jacobs SA; Friedland DM; Shin DM; Chatta GS; Tutchko S; Zamboni WC
Cancer Chemother Pharmacol; 2005 Apr; 55(4):354-360. PubMed ID: 15723261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
